No Data
No Data
United Therapeutics Says Idiopathic Pulmonary Fibrosis Treatment Study Reaches Full Enrollment
United Therapeutics (UTHR) said Wednesday its late-stage study of Tyvaso inhalation solution to treat idiopathic pulmonary fibrosis has reached full enrollment.The 597-patient TETON 2 study will
United Therapeutics Announced Full Enrollment Of The TETON 2 Study Of Tyvaso (Treprostinil) Inhalation Solution (Nebulized Tyvaso) For Idiopathic Pulmonary Fibrosis, Top Line Data Expected In The Second Half Of 2025
United Therapeutics Announced Full Enrollment Of The TETON 2 Study Of Tyvaso (Treprostinil) Inhalation Solution (Nebulized Tyvaso) For Idiopathic Pulmonary Fibrosis, Top Line Data Expected In The
Express News | United Therapeutics Corp - Top Line Data Expected in Second Half of 2025
Express News | United Therapeutics Corporation Announces Full Enrollment of the Teton 2 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis
United Therapeutics(UTHR.US) Officer Sells US$2.27 Million in Common Stock
$United Therapeutics(UTHR.US)$ Officer ROTHBLATT MARTINE A sold 7,200 shares of common stock on Jul 5, 8, 2024 at an average price of $315.1507 for a total value of $2.27 million.Source:
Citi Research's AI Hedge Stocks - Part II